Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Theravance Biopharma Inc
TBPH | US
17.23
USD0.45
2.68%
TBPH | US
About Theravance Biopharma Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/04/2026
Close
17.23
Open
16.97
High
17.24
Low
16.74
Theravance Biopharma Inc. a biopharmaceutical company discovers develops and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI a once-daily nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program as well as Viatris Inc. Theravance Biopharma Inc. was incorporated in 2013 and is based in George Town the Cayman Islands.
View LessTBPH | US
Risk
29.2
Sharpe
1.74
Luna's Score
64/100
Recommendation
Hold
Luna says (TBPH | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
19.6%1 month
29.2%3 months
63.1%6 months
60.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
9.91
Price to book
2.18
Debt to equity
0.24
Debt to assets
0.13
Ent. to EBITDA
-9.69
Ent. to rev.
6.00
PEG
-0.05
Other Fundamentals
EBITDA
-39.17M
MarketCap
842.93M
MarketCap(USD)
842.93M
Div. yield
-
Op. margin
-89.46
Erngs. growth
-
Rev. growth
3.70
Ret. on equity
-19.27
Short ratio
24.09
Short perc.
20.90
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.22
Range1M
3.84
Range3M
7.95
Volumes: Market Activity
Rel. volume
0.73
Price X volume
7.02M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -9.69 | - | Cheaper |
| Ent. to Revenue | 6.00 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.18 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 63.05 | - | Par |
| Debt to Equity | 0.24 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 842.93M | - | Emerging |
